Trends in Early Outpatient Drug Therapy in Pediatric Inflammatory Bowel Disease in Finland: A Nationwide Register-Based Study in 1999–2009
Table 3
Drug therapy strategies during the first 6 months among pediatric patients with inflammatory bowel disease () by three different periods between the years 1999 and 2009.
Medication
1999–2005
2006-2007
2008-2009
valuea
(%)
(%)
(%)
for linear trend
Crohn’s disease
Local therapy only (5-ASA and/or corticosteroid)
2
(5.3)
0
0
Single therapy with 5-ASA
10
(26.3)
15
(28.3)
20
(20.6)
Single therapy with corticosteroid
3
(7.9)
1
(1.9)
0
Combination therapy with 5-ASA and corticosteroid
16
(42.1)
21
(39.6)
34
(35.1)
Combination therapies with azathioprineb
7
(18.4)
16
(30.2)
43
(44.3)
0.027
In total
38
(100.0)
53
(100.0)
97
(100.0)
Ulcerative colitis
Local therapy only (5-ASA and/or corticosteroid)
2
(1.8)
0
2
(2.0)
Single therapy with 5-ASA
39
(35.8)
29
(33.7)
18
(18.4)
Combination therapy with 5-ASA and corticosteroid
52
(47.7)
36
(41.9)
58
(59.2)
Combination therapies with azathioprineb
16
(14.7)
21
(24.4)
20
(20.4)
0.776
In total
109
(100.0)
86
(100.0)
98
(100.0)
aAdjusted for age; trend was not analyzed for corticosteroid and 5-ASA because prednisolon 5 mg tablets were not reimbursed in Finland between the years 2006 and 2007. bIncluding systemic 5-ASA or/and corticosteroid.
